LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants

Molecular and Cellular Biochemistry

Volumn 188, Issue 1-2, 1998, Pages 149-159

  Aviram, Michael ^a,b   Fuhrman, Bianca ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Antioxidants; Atherosclerosis; Carotenoids; Lipid peroxidation; Lipoproteins; Macrophages; Polyphenols

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; BEZAFIBRATE; CAPTOPRIL; CHOLESTEROL; COLESTYRAMINE; ENALAPRIL; FLAVONOID; FLUINDOSTATIN; GEMFIBROZIL; GLABRIDIN; GLUTATHIONE; LIPID; LIPOPROTEIN; LIPOXYGENASE; LOSARTAN; LOW DENSITY LIPOPROTEIN; LYCOPENE; MEVINOLIN; MONOUNSATURATED FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; PRAVASTATIN; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; FOAM CELL; GLYCYRRHIZA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LIPID PEROXIDATION; MACROPHAGE; NONHUMAN; NORMAL HUMAN; OXIDATIVE STRESS; SMOOTH MUSCLE; THROMBOSIS;

ANIMALS; ANTIOXIDANTS; ARTERIES; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MACROPHAGES; OXIDANTS; OXIDATION-REDUCTION;

ANIMALIA; GLYCYRRHIZA;

EID: 0031757519     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006841011201     Document Type: Conference Paper

References (76)

1. Aviram M: Oxidized low density lipoprotein (Ox-LDL) interaction with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 34: 599-608,1996
2. Aviram M: Oxidative modification of low density lipoprotein and atherosclerosis. Isr J Med Sci 31: 241-249,1993
3. Aviram M: LDL-Platelet interaction under oxidative stress induces macrophage foam cell formation. Thromb Haemost 74(1): 360-364,1993
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 913-924,1989
5. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al.: Atherosclerosis: Basic mechanisms. Oxidation, inflammation and genetics. Circulation 91: 2488-2498,1993
6. Aviram M: The contribution of the macrophage receptor for oxidized LDL to its cellular uptake. Biochem Biophys Res Commun 179: 339-363,1991
7. Keidar S, Brook JO, Rosenblat M, Fuhrman B, Dankner G, Aviram M: Involvement of the macrophage LDL receptor binding domains in the uptake of oxidized LDL. Arterioscler Thromb Vasc Biol 12(4): 484-493,1992
8. Eisenberg S, Shayek E, Olivecrona T, Vlodavsky I: Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest 90: 2013-2021,1992
9. Williams KJ, Mess GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL: Mechanisms by which lipoprotein lipase alters cellular metabolism of LP(a) LDL and nascent lipoporoteins. J Biol Chem 267: 13284-13292,1992
10. Auerhach BJ, Bisgaier CL, Wolle J, Saxena U: Oxidation of low density lipoproteins greatly enhances their association with lipoprotein lipase anchored to endothelial cell matrix. J Biol Chem 271: 1329-1333,1996
11. Kaplan M, Williams JK, Mandel H, Aviram M: Role of macrophage glycosaminoglycans in the cellular catabolism of oxidized LDL, by macrophages. Arterioscler Thromb Vasc Biol 18: 542-553,1998
12. Kaplan M, Aviram M: Oxidized LDL binding to a macrophage-secreted extracellular matrix. Biochem Biophys Res Commun 237: 271-276,1997
13. Aviram M, Maor I, Keidar S, Hayek T, Oiknine J, Bar-El Y, Adler Z, Kertzman V, Milo S: Lesioned low density lipoprotein in atherosclerotic apolipoprotein E deficient transgenic mice and in humans is oxidized and aggregated. Biochem Biophys Res Commun 216: 501-513,1995
14. Hayek T, Oiknine J, Brook JG, Aviram M: Increased plasma lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 201: 1567-1574,1994
15. Yla-Herttuala S, Palinski W, Rosenfeld ME, Pharthasarathy S, Carew TE, Buttler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 10867-1095,1989
16. Heberland ME, Fogelman AM: The role of altered lipoprotein in the pathogenesis of atherosclerosis. Am Heart J 113: 573-517,1987
17. Lavy A, Brook JG, Dankner G, Ben Amotz A, Aviram M: Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 40: 794-799,1991
18. Keidar S, Kaplan M, Shapira H, Brook JG, Aviram M: Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: A possible role for angiotensin II. Atherosclerosis 104: 71-84,1994
19. Bergman R, Kasif Y, Aviram M, Maor I, Ullman Y, Gdal-on M, Friedman-Birnbaum R: Normolipidemic xanthelasma palpebrarum: Lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 76: 107-110,1996
20. Hussein O, Rosenblat M, Refael G, Aviram M: Dietary selenium increases cellular glutahtione peroxidase activity and reduces the enhanced susceptibility to lipid peroxidation of plasma and low density lipoprotein in kidney transplanted recipients. Transplantation 63: 679-685,1997
21. Pipek R, Dankner G, Ben-Amotz A, Aviram M, Levy Y: Increased plasma oxidizability in subjects with severe obesity. J Nutr Environ Med 6: 267-272,1996
22. Lavy A, Ben-Amotz A, Aviram M: Increased susceptibility to lipid peroxidation of chylomicrons and low density lipoprotein in celiac disease. Ann Nutr Metabol 37: 68-74,1993
23. Maggi E, Bellazzi R, Gazo A, Secciam T, Bellomo G: Autoantibodies against oxidatively-modified LDL, in chronic patients undergoing dialysis. Kidney Intern 46: 869-876,1994
24. Nishigaki I, Hagihara M, Tsunekana H, Maseki M, Yagi K: Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 25: 373-378,1981
25. Aviram M, Keidar S, Brook JG: Dual effect of lovastatin and simvastatin on LDL-macrophage interaction. Europ J Clin Chem Clin Biochem 29(10): 657-664,1991
26. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG: Lovastatin inhibits LDL oxidation and alters its fluidity and uptake by macrophages: vitro and in vivo studies. Metabolism 41(3): 229-235,1992
27. Hoffman R, Brook JG, Aviram M: Hypolipidemic therapy reduces lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies. Atherosclerosis 93: 105-113,1992
28. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M: Reduced susceptibility of LDL to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 128: 11-18,1997
29. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S: Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 31: 39-45,1998
30. Aviram M, Rosenblat M, Bisgaier CL, Newton RS: Atorvastatin and gemfibrozil metabolises, but not the parent drugs are potent antioxidants against lipoproteins oxidation. Atherosclerosis (in press) 1998
31. Keidar S, Attias J, Smith J, Breslow JL, Hayek T: The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 236(3): 622-625,1997
32. Aviram M, Kasem E: Dietary olive oil reduces the susceptibility of low density lipoprotein to lipid peroxidation and inhibits lipoprotein uptake by macrophages. Ann Nutr Metabol 37: 75-84,1993
33. Fuhrman B, Lavy A, Aviram M: Consumption of red wine with meals reduces the susceptibility of human plasma and LDL to undergo lipid peroxidation. Am J Clin Nutr 61: 549-554,1995
34. Fuhrman B, Aviram M: White wine reduces LDL susceptibility to oxidation in vitro but not in vivo. Am J Clin Nutr 63: 403-404,1996
35. Lavy A, Fuhrman B, Markel A, Dankner G, Ben Amotz A, Presser D Aviram M: The effect of dietary supplementation of red or white wine on human blood chemistry, hematology and coagulation pattern: favorable effect of red wine on plasma high density lipoprotein. Ann Nutr Metabol 38: 287-294,1994
36. Hayek T, Fuhrman B, Via J, Rosenblat M, Belinky P, Coleman R, Elis A, Aviram M: Reduced progression of atherosclerosis in the apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and to aggregation. Arterioscler Thromb Vasc Biol 17: 2744-2752,1997
37. Vaya J, Belinky P, Aviram M: Antioxidant constituents from licorice roots: Isolation, structure elucidation and antioxidative capacity towards LDL oxidation. Free Radie Biol Med 23: 302-313,1997
38. Fuhrman B, Buch S, Vaya J, Belinky PA, Coleman R, Hayek T, Aviram M: Licorice extract and its major polyphenol glabridin protect LDL against lipid peroxidation: In vitro and ex-vivo studies in humans and in the atherosclerotic apolipoprotein E deficient mice. Am J Clin Nutr 66: 267-275,1997
39. Rosenblat M, Aviram M: Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL. Free Radie Biol Med 24: 305-317,1997
40. Oiknine J, Aviram M: Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler Thromb Vasc Biol 12: 745-753,1992
41. Carter D, Fuhrman B, Aviram M: Macrophage activation with phorbol myristate acetate is associated with cellular lipid peroxidation. Isr J Med Sci 32(6): 479-485 1996
42. Hoff HF, O'Neil J: Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb 11: 1209-1222,1991
43. 2+'-induced oxidation. Biochem J 310: 417-426,1995
44. Maori I, Hayek T, Coleman R, Aviram M: Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 17: 2995-3005,1997
45. Levy Y, Ben Amotz A, Dankner G, Brook JG, Aviram M: Enhanced lipid peroxidation of low density lipoprotein by fish oil. J Optimol Nutr 2: 6-9,1993
46. Krinsky NI: Antioxidant functions of carotenoids. Free Radic Biol Med 7: 617-635,1989
47. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belangen C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145-1149,1996
48. Jialal I, Norkus EP, Cristor L, Grundy SM: β-Carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 134-138,1991
49. Sies W, Stahl W, Sundquist AR: Antioxidant functions of vitamins: vitamin E and C, Beta-carotene, and other carotenoids. In: H.E. Savberlich, L.Y. Machlin (eds). Beyond deficiency: New views on the function and health effects of vitamins. Ann NY Acad Sci 669: 7-20,1992
50. Lavy A, Ben Amotz A, Aviram M: Preferential inhibition of LDL oxidation by the all-trans isomer of β-carotene in comparison to the 9-cis-carotene. Eur J Clin Chem Clin Biochem 31: 83-90,1993
51. Levy Y, Ben-Amotz A, Aviram M: Effect of dietary supplementation of β-Carotene to humans on its binding to plasma LDL and on the lipoprotein susceptibility to undergo oxidative modification: Comparison of the synthetic all Irans isomer with the natural algae β-carotene. J Nutr Env Med 5: 13-22,1995
52. Levy Y, Kaplan M, Ben Amotz A, Aviram M: The effect of dietary supplementation of β-carotene on human monocyte-macrophage-mediated oxidation of low density lipoprotein. Isr J Med Sci 32(6): 473-478,1996
53. Fuhrman B, Ben-Yaish L, Attias J, Hayek T, Aviram M: Tomato's lycopene and β-carotene inhibit low density lipoprotein oxidation and this effect depends on the lipoprotein vitamin E content. Nutr Metab Cardiovasc Dis 7: 433-443,1997
54. Chandler RF: Licorice, more than just a flavour. Can Pharm J 118: 420-424,1985
55. Demizu S, Kajiyama K, Takahashi K, Hiraga Y, Yamamoto S, Tamura Y, Okada K, Kinoshita T: Antioxidant and antimicrobial constituents of Licorice: Isolation and structure elucidation of a new benzofuran derivative. Chem Pharm Bull 36: 3474-3479,1988
56. Aviram M, Rosenblat M: Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J Lipid Res 35: 385-398,1994
57. Aviram M, Rosenblat M, Etzioni A, Levy R: Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein. Metabolism 45(9): 1069-1079,1996
58. 2 and phospholipase D are involved in macrophage NADPH oxidase-mediated oxidation of LDL. Isr J Med Sci 32: 749-756,1996
59. Fuhrman B, Oiknine J, Aviram M: Iron induces lipid peroxidation in cultured macrophages increases their ability to oxidatively modify LDL and affect their secretory properties. Atherosclerosis 111: 65-78,1994
60. Keidar S, Kaplan M, Hoffman A, Brook JG, Aviram M: Angiotensin II stimulates macrophage-mediated lipid peroxidation of low density lipoprotein. Atherosclerosis 115: 201-215,1995
61. Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A: The effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 39: 475-478,1996
62. Fuhrman B, Oiknine J, Keidar S, Ben-Yaish L, Kaplan M, Aviram M: Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of further progressive LDL oxidation. Free Radie Biol Med 23: 34-46,1997
63. Baker RD, Baker SS, LaRosa K: Selenium regulation of glutathione peroxidase in human hepatoma cell line Hep 3B. Arch Biochem Biophys 304: 53-57,1993
64. Kuzuya M, Natio M, Funakui C, Hayashi T, Asai K, Kuzuya F: Protective role of intracellular glutathione against oxidized low density lipoprotein in cultured endothelial cells. Biochem Biophys Res Commun 163(3): 1466-1472,1989
65. Gotoh N, Graham A, Niki E, Darly-Usmar UM; Inhibition of glutahtione synthesis increases the toxicity of oxidized low-density lipoprotein to human monocytes end macrophages. Biochem J 296: 151-154,1994
66. Mackness MI, Abbott C, Arrol S, Durrington PN: The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294: 829-834,1993
67. Hayek T, Oiknine J, Dankner G, Brook JG, Aviram M: HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: Studies in transgenic mice. Eur J Clin Chem Clin Biochem 33: 721-725,1995
68. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115: 243-253,1995
69. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104: 129-135,1993
70. Mackness MI, Arrol S: Durrington PN Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 286: 152-154,1991
71. Navab M, Berliner JA, Watson AD, Hama SY, Teritto MC, Lusis AJ, Shih DM, Van Lenten DJ, Frank JS, Demer LL, Edwards PA, Fogelman AM: The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 16: 831-842,1996
72. La Du BN: Structural and functional diversity of paraoxonases. Nature Medicine 2(11): 1186-1187,1996
73. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7: 69-76,1996
74. Mackness MI, Harty D, Bhatangar D, Winocour PH, Arrol S, Ishola M, Durrington PN: Serum Paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193-199,1991
75. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 11: 1812-1818,1993
76. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590, 1998